|
⚲
|
| Keyboard |
| EcoR1 Capital LLC
✚
|
|
|---|---|
| CRD # | 167121 |
| SEC # | 801-100470 |
| CIK # | 0001587114 |
| AUM | 3,424.7 M (2026-03-30) |
| Employees | 22 (41% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 415-754-3517 |
| Address | 357 Tehama Street San Francisco, CA 94103 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| In the News | |
|---|---|
| Tue, 28 Jul 2026 | EcoR1 Capital LLC Takes Position in Stoke Therapeutics, Inc. $STOK — MarketBeat |
| Tue, 28 Jul 2026 | EcoR1 Capital LLC Cuts Stock Holdings in Xencor, Inc. $XNCR — MarketBeat |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Zymeworks Inc | 0.6 | ||
| Anaptysbio Inc | 0.4 | ||
| Jazz Pharmaceuticals Inc | 0.3 | ||
| Crinetics Pharmaceuticals Inc | 0.2 | ||
| Oric Pharmaceuticals Inc | 0.1 | ||
| CG Oncology Inc | 0.1 | ||
| CRISPR Therapeutics AG | 0.1 | ||
| Eton Pharmaceuticals Inc | 0.1 | ||
| Xencor Inc | 0.0 | ||
| Aquinox Pharmaceuticals Inc | 0.0 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| VC | EcoR1 Venture Opportunity Fund LP | [2019-08-29] | 5.5 M | 65.4 M |
| Filed 2020-05-08 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $2,000,000 · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| HF | EcoR1 Special Opportunity Fund II LP | [2016-03-29] | 0.6 M | |
| Filed 2015-11-06 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $500,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | EcoR1 Special Opportunity Fund I LP | [2015-03-30] | 8.8 M | |
| Filed 2015-02-17 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $500,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | EcoR1 Capital Fund LP | [2014-03-25] | 117.8 M | 229.0 M |
| Filed 2026-01-22 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Minimum $25,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | EcoR1 Capital Fund Qualified LP | [2014-03-25] | 1,811.4 M | 3,130.2 M |
| Filed 2026-01-22 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $25,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 5 | 3.4 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 5 | 3.4 |
| By Discretionary | ||
| Discretionary | 5 | 3.4 |
| Non-Discretionary | 0 | 0.0 |
| Total | 5 | 3.4 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.7 | |
| United States Persons | 2.8 | |
| Total | 5 | 3.4 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Oleg Nodelman | Executive Officer | 14 | 3 | |
| Scott Perlen | Executive Officer | 8 | 2 | |
| Sarah Marriott | Executive Officer | 7 | 2 | |
| EcoR1 Capital LLC | Executive Officer | 5 | 2 | |
| Biotech Opportunity GP LLC | Executive Officer | 2 | 2 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001587114] | |
| 3 | [0001587114] | |
| 4 | [0001587114] | |
| SC 13D | [0001587114] | |
| SC 13G | [0001587114] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 254900G27UH5KKYMY240 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Aktis Oncology Inc AKTS
Common Stock
|
2026-01-12 | Buy | 2,077,779 | $18.00 | 37,400,022 |
|
Aktis Oncology Inc AKTS
Common Stock
|
2026-01-12 | Conversion | 128,506 | ||
|
Aktis Oncology Inc AKTS
Common Stock
|
2026-01-12 | Conversion | 202,862 | ||
|
Aktis Oncology Inc AKTS
Common Stock
|
2026-01-12 | Conversion | 2,270,879 | ||
|
Aktis Oncology Inc AKTS
Common Stock
|
2026-01-12 | Buy | 144,443 | $18.00 | 2,599,974 |
|
Aktis Oncology Inc AKTS
Series A Redeemable Convertible Preferred Stock · derivative
|
2026-01-12 | Conversion | 9,913,810 | ||
|
Aktis Oncology Inc AKTS
Series A Redeemable Convertible Preferred Stock · derivative
|
2026-01-12 | Conversion | 997,299 | ||
|
Aktis Oncology Inc AKTS
Series A Redeemable Convertible Preferred Stock · derivative
|
2026-01-12 | Conversion | 488,891 | ||
|
Aktis Oncology Inc AKTS
Series B Redeemable Convertible Preferred Stock · derivative
|
2026-01-12 | Conversion | 2,397,500 | ||
|
Aktis Oncology Inc AKTS
Class A Common Stock · derivative
|
2026-01-12 | Conversion | 965,190 | ||
|
Aktis Oncology Inc AKTS
Class A Common Stock · derivative
|
2026-01-12 | Conversion | 86,222 | ||
|
Aktis Oncology Inc AKTS
Series B Redeemable Convertible Preferred Stock · derivative
|
2026-01-12 | Conversion | 102,500 | ||
|
Adaptimmune Therapeutics PLC ADAP
Ordinary Shares
|
2025-07-30 | Sell | 27,433,338 | $0.10 | 2,743,334 |
|
Adaptimmune Therapeutics PLC ADAP
Ordinary Shares
|
2025-07-29 | Sell | 2,687,460 | $0.10 | 268,746 |
|
Adaptimmune Therapeutics PLC ADAP
Ordinary Shares
|
2025-07-28 | Sell | 33,931,740 | $0.11 | 3,732,491 |
|
Zymeworks Inc ZYME
Pre-Funded Warrants (right to acquire) · derivative
|
2025-06-26 | Option exercise | 5,086,521 | $0.00 | |
|
Zymeworks Inc ZYME
Common Stock
|
2025-06-26 | Option exercise | 5,086,480 | $0.00 | |
|
Zymeworks Inc ZYME
Common Stock
|
2025-06-26 | Tax withheld | 41 | $12.71 | 521 |
|
Zymeworks Inc ZYME
Common Stock
|
2025-05-19 | Buy | 5,919 | $11.78 | 69,726 |
|
Zymeworks Inc ZYME
Common Stock
|
2025-05-15 | Buy | 49,502 | $11.43 | 565,808 |
| showing 20 of 159 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Marble Bar Asset Management LLP
✚
|
3,568.3 M | |
|
JAHD Management Company LLC
✚
|
MA | 3,557.9 M |
|
Burkehill Global Management LP
✚
|
NY | 3,536.9 M |
|
Dragonfly Digital Management LLC
✚
|
CA | 3,437.5 M |
|
Carronade Capital Management LP
✚
|
CT | 3,431.8 M |
|
Caption Management LLC
✚
|
OK | 3,407.7 M |
|
Lakewood Capital Management LP
✚
|
NY | 3,398.7 M |
|
Invenomic Capital Management LP
✚
|
MA | 3,392.8 M |
|
Atalan Capital Partners LP
✚
|
NY | 3,290.1 M |
|
Verger Capital Management LLC
✚
|
NC | 3,283.7 M |